Career Development Awards will be used to support the development of careers in translational pancreatic cancer research by individuals from one of the following categories: 1) clinical fellows in medical oncology, gastroenterology, pathology, or surgery; 2) junior faculty members at the instructor or assistant professor level, either clinical faculty who seek training and an opportunity to establish a career that includes basic science research, or basic science faculty who want additional training or an opportunity to undertake translational research; 3) senior postdoctoral fellows who are at the point of entering the academic ranks and establishing independent research programs; 4) established clinical faculty who require additional training in basic or translational research in order to establish a translational research program. We will support one new candidate in each year of the grant at a level of $150,000 per year for up to two years for each award ($75,000 will be provided by the SPORE program and $75000 will be provided in matching funds by the UNMC Eppley Cancer Center). Individuals in this program are required to commit substantial effort (a minimum of 50%, and higher percent efforts are strongly encouraged and will receive preferential selection) to SPORE related translational research. Funds can be used for salaries or any other aspect of development (research costs) that are deemed necessary for the candidate to succeed in establishing a translational pancreatic cancer research program. Progress is reviewed after the first year and there is a decision to continue support or redirect the efforts of the candidate into another area of research if there is insufficient progress. The candidate is required to submit an NIH G or R series grant application during the second year of the award, that is primarily focused on pancreatic cancer research.
In considering the needs of the pancreas research community, and the needs of our program of translational research in pancreatic cancer, we have identified 5 specific areas of need in different research disciplines: GI oncology, GI surgery, Gastroenterology, Pathology, and Basic Research. It is our goal to recruit and develop 2-3 new faculty members who are committed to work in translational research pancreatic cancer in any of these disciplines over the 5 year period of the SPORE award.
|Attri, Kuldeep S; Murthy, Divya; Singh, Pankaj K (2017) Racial disparity in metabolic regulation of cancer. Front Biosci (Landmark Ed) 22:1221-1246|
|Wu, Guangyin; Verma, Vivek; Haefner, Matthias F et al. (2017) Feasibility and reproducibility of substituting oral contrast with water for duodenal volume delineation in patients undergoing pancreatic stereotactic body radiotherapy. J Gastrointest Oncol 8:705-709|
|Verma, Vivek; Lazenby, Audrey J; Zheng, Dandan et al. (2017) Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial. Radiother Oncol 122:464-469|
|Karmakar, Saswati; Seshacharyulu, Parthasarathy; Lakshmanan, Imayavaramban et al. (2017) hPaf1/PD2 interacts with OCT3/4 to promote self-renewal of ovarian cancer stem cells. Oncotarget 8:14806-14820|
|Shukla, Surendra K; Purohit, Vinee; Mehla, Kamiya et al. (2017) MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell 32:71-87.e7|
|King, Ryan J; Yu, Fang; Singh, Pankaj K (2017) Genomic alterations in mucins across cancers. Oncotarget :|
|Krishn, Shiv Ram; Kaur, Sukhwinder; Sheinin, Yuri M et al. (2017) Mucins and associated O-glycans based immunoprofile for stratification of colorectal polyps: clinical implication for improved colon surveillance. Oncotarget 8:7025-7038|
|Gautam, Shailendra K; Kumar, Sushil; Cannon, Andrew et al. (2017) MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. Expert Opin Ther Targets 21:657-669|
|Abrego, Jaime; Gunda, Venugopal; Vernucci, Enza et al. (2017) GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Cancer Lett 400:37-46|
|Souchek, Joshua J; Davis, Amanda L; Hill, Tanner K et al. (2017) Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells. Mol Cancer Ther 16:1819-1830|
Showing the most recent 10 out of 163 publications